Allogeneic hematopoietic SCT (HSCT) is currently the only curative treatment for myelodysplastic syndrome (MDS). However, many patients cannot find an HLAmatched donor. We have developed a new protocol for HLA-mismatched (including haploidentical) HSCT using G-CSF-primed BM plus G-CSF-mobilized PBSCs without in vitro T-cell depletion. A total of 36 patients diagnosed with high-risk MDS (RAEB (refractory anemia with excess blasts) or RAEBt (RAEB in transformation)) underwent transplantation from HLA-mismatched family donors. All patients achieved sustained myeloid engraftment. The cumulative incidence of grades II-IV acute GVHD (aGVHD) was 60% and that of grades III and IV aGVHD was 15%. The 2-year cumulative incidence of chronic GVHD was 56%. After a median follow-up of 17 months, 4 patients had relapsed and died and 25 patients were still alive. The 2-year probability of leukemia-free survival (LFS) was 65%. Patients transplanted within 7 months of diagnosis had better LFS (89 vs 43% ). Severe aGVHD decreased the LFS significantly by increasing non-relapse mortality (NRM). This study confirms that HLA-mismatched HSCT is a treatment option for MDS. Patients with high-risk MDS benefit from receiving HSCT early in the course of the disease.
Introduction
Allogeneic hematopoietic SCT (HSCT) is the only curative treatment available for high-risk myelodysplastic syndrome (MDS).
1 Donor availability limits the use of HSCT, and the use of alternative donors is worth exploring. We have recently developed a new method for HLA-mismatched/ haploidentical HSCT using G-CSF-primed BM (G-BM) plus G-CSF-mobilized PBSCs (G-PB) without ex vivo T-cell depletion after conditioning with a modified BU/CY2 plus thymoglobuline (ATG) regimen. The results for this novel method in acute leukemia and chronic myeloid leukemia patients are promising. 2, 3 However, there has been no report on its effects on MDS until now.
We report the results of HSCT from haploidentical/ mismatched donors in 36 MDS patients using this protocol.
Patients and methods
A total of 36 consecutive patients who were diagnosed with MDS and received an HLA-mismatched allogeneic HSCT without in vitro T-cell depletion from April 2003 to September 2008 at the Peking University Institute of Hematology, People's Hospital, were analyzed. The institutional review board at the Peking University Institute of Hematology approved the protocol, and all patients or their guardians signed consent forms approved by the institutional review board.
Myelodysplastic syndrome was originally diagnosed by the FAB criteria 4 and then more recently reclassified according to the criteria defined by the World Health Organization (WHO). 5 The International Prognostic Scoring System (IPSS) was used to categorize the patients into different risk groups. 6 Only patients who were diagnosed with MDS-refractory anemia with excess blasts (RAEB) or MDS-RAEB in transformation (RAEBt) were included. The enrolled patients met the following criteria: no available HLA-identical related or unrelated donors, sufficient cardiac function, creatinine clearance 470 ml/ min, lung diffusion capacity of at least 80%, transaminases less than three times the upper limit of normal, Karnofsky performance status X80% and no active infections.
Five patients had been reported on in a previous paper. 2 Patient characteristics are summarized in Table 1 . Followup for all patients extended through to 31 January 2009.
Donors
Family members were assessed for the degree of mismatch. HLA-A and HLA-B typing was performed by intermediate-resolution DNA typing, whereas HLA-DRB1 and HLA-C typing was performed using high-resolution DNA techniques. The degree of HLA mismatch is shown in Table 1 . More than half the donors (n ¼ 19) were not siblings. Family donors were ranked on the basis of best HLA match, age (younger preferred) and health status.
Conditioning regimen
A modified BU/CY2 þ ATG was used for conditioning therapy, which consisted of cytarabine (4 g/m 2 per day) i.v. on days À10 to À9; BU (3.2 mg/kg per day) i.v. on days À8 to À6; CY (1.8 g/m 2 per day) i.v. on days À5 to À4; Me-CCNU (250 mg/m 2 ) orally once on day À3; and ATG (2.5 mg/kg per day; Sangstat, Lyon, France) i.v. for 4 consecutive days from days À5 to À2.
Collection of hematopoietic cells
Granulocyte colony-stimulating factor (5 mg/kg per day) was used to collect G-BM and G-PB. G-BM was harvested on day 4 after G-CSF and G-PB on day 5. The target mononuclear cell count was X6 Â 10 8 per kg recipient patient weight. Fresh unmanipulated G-BM and G-PB were infused into the recipient on the day of collection. In instances of ABO major blood group incompatibility, red cells were removed by density gradient sedimentation with Hespan.
Supportive care
All patients were nursed in single rooms with HEPAfiltered air and received prophylactic antibiotics if their ANC was less than 1 Â 10 9 /l. Fluconazole was given to all patients from day À5 to day 30. Trimethoprim/sulfamethoxazole was administered for prophylaxis against Pneumocystis jiroveci infection. Acyclovir was given as Herpes prophylaxis from day 1 until day 180. Patients were monitored weekly for CMV infection by PCR. CMVpositive patients were treated with either ganciclovir or foscarnet. All blood products were irradiated (2500 cGy) before infusion. GVHD prophylaxis and treatment GVHD prophylaxis included CsA (1.25 mg/kg) given from day À9 to 6 months post transplantation. The dose of CsA was adjusted after monitoring serum levels to maintain a trough level between 150 and 250 ng/ml, and was tapered from day 90 such that it was discontinued on day 180. MTX (15 mg/m 2 ) was given on day 1 and 10 mg/m 2 MTX was given on days 3, 6 and 11 post transplantation. Chronic GVHD (cGVHD) was evaluated in patients surviving more than 100 days with sustained engraftment. The criteria for grading acute GVHD (aGVHD) and cGVHD were previously published. 7, 8 aGVHD was treated with steroids (methylprednisolone (0.5-1 mg/kg per day)). When the grade of GVHD was II or greater, MTX was added if deemed necessary by clinical judgment. If there was either inadequate or no response to primary therapy, anti-CD25 MoAbs (basiliximab, Novartis Pharma AG, Basle, Switzerland or Zenapax, Hoffmann-La Roche Corp, Nutley, NJ, USA) were administered to the patient. cGVHD was treated with CsA and steroids.
Engraftment and rejection
The day of engraftment was defined as the first day of three consecutive post transplantation days on which the ANC exceeded 500 per ml. Patients who did not achieve this level of ANC at any time after transplantation were considered to have primary graft failure. Patients with initial engraftment in whom a severely hypocellular marrow and ANC of o500 per ml recurred for more than 3 days were considered to have secondary or late graft failure. Patients who survived at least 28 days were considered evaluable for engraftment.
Relapse and chimerism analyses
All patients were scheduled to have their marrow samples examined morphologically as well as by cytogenetic and flow cytometric analyses on days 30, 60, 90 and 180 after HSCT, and then annually or as clinically indicated. Relapse was defined as the reemergence of dysplastic cells in the marrow or aberrant precursors defined with the use of flow cytometry. If the patient was diagnosed with disease relapse, donor lymphocytes were infused as described in a previous report. 9 Lymphocytes were obtained from cryopreserved G-PB or from fresh G-PB. The Peking University Review Board approved the cryopreservation, remobilization and infusion of the G-PB. All donors and patients signed a consent form relating to these procedures.
Chimerism was evaluated on recipient BM cells usually on days 30, 180 and 365 after HSCT by cytogenetic G-banding or FISH. When the patient and donor were of the same sex, chimerism was assessed using PCR-based analyses of polymorphic minisatellite or microsatellite regions (variable number tandem repeat).
Statistical analysis
The probabilities of OS, leukemia-free survival (LFS), nonrelapse mortality (NRM) and relapse rate (RR) were estimated by the Kaplan-Meier method. Potential prognostic factors for OS, RR and NRM were evaluated in univariate analyses by the log-rank test, with a P-value o0.05 considered statistically significant. All statistical analyses were done by SPSS 16.0 (SPSS Inc, Chicago, IL, USA). The occurrence of aGVHD and cGVHD was calculated using cumulative incidence estimates, taking into account the competing risk structure.
Results
There were 27 males and 9 females. The median time from diagnosis to HSCT was 7 months (range 1.5-204 months). A total of 15 patients received chemotherapy before HSCT, 7 of whom achieved a first hematological CR. The remaining eight patients accounted for the 'non-remission' group, because they exhibited either a partial response or they had stable or progressive disease after chemotherapy. The other 21 patients had received no chemotherapy and were also included in the non-remission group.
Engraftment
All 36 patients achieved sustained myeloid engraftment. At least two of three methods (HLA DNA typing, PCR-DNA fingerprinting and FISH) were used to confirm 100% donor chimerism in all of the patients. The median time to reach an ANC above 0.5 Â 10 9 cells per l was 12 days (range 9-29 days). In total, 32 patients had plt engraftment during the follow-up period, and the median time to reach a plt count above 20 Â 10 9 cells per l was 14 days (range 8-67 days). No variants, such as gender, age, diagnosis, source of donors, duration of disease, therapy before transplantation and the extent of HLA mismatching, affected myeloid or plt recovery.
GVHD and opportunistic infections
All 36 patients with engraftment survived at least 28 days and were evaluable for the development of aGVHD. A total of 16 patients had grade II aGVHD, 2 had grade III aGVHD and 2 had grade IV aGVHD. The cumulative incidence rates at 100 days after HSCT of grades II-IV aGVHD and of grades III and IV aGVHD were 60.30 ± 8.7% and 15.20 ± 7.1%, respectively. Factors that might influence the incidence of aGVHD were analyzed, including age, gender of the patients and donors, HLA disparity, stage of disease before transplantation, IPSS score and duration of disease. None of these factors were found to influence the incidence of aGVHD.
A total of 31 patients survived more than 100 days after transplantation and were evaluated for cGVHD. cGVHD occurred in 18 patients, 12 of whom developed limited cGVHD, whereas 6 developed extensive cGVHD. The cumulative incidence rate for cGVHD after 2 years was 56.4 ± 10.4%. The development of cGVHD was not associated with the gender or age of the patients and donors, the diagnosis, the source of donors, the duration of disease, the therapy before transplantation or the extent of HLA mismatching.
Cytomegalovirus viremia was seen in 23 cases. Another four patients developed CMV disease: two with CMV pneumonia, one with CMV enteritis and one had both. Hemorrhagic cystitis developed in 11 patients. Besides these, a total of 29 occurrences of opportunistic infections
were recorded in 23 patients during the follow-up time. The lung was the most infected organ (27 occurrences), other affected organs were the gastrointestinal tract (4 occurrences) and the urinary system (1 case). The pathogens diagnosed to cause the infections were bacteria in 11 cases, fungi in 7 cases and combined infections or unknown pathogens in the remaining 11 occurrences.
Relapse
As of 31 January 2009, four patients had recurrent disease after a median of 17 months (range 2.0-55 months), reaching a cumulative incidence of relapse of 19.25±9.37% at 2 years. Three of the four patients with recurrent disease were diagnosed with FAB-RAEBt and one was diagnosed with FAB-RAEB. All of these patients had received chemotherapy before HSCT, but only the patient with RAEB achieved CR. After relapse, all the patients received chemotherapy followed by infusion of G-PB from the same donor to treat the relapse. Only the patient diagnosed with RAEB achieved CR and remained in CR for nine subsequent months, but he developed grade II aGVHD and subsequently died of a pulmonary fungal infection. The remaining three patients showed no response or only a temporary response to the donor lymphocyte infusion and died of their disease recurrence.
Factors that might affect relapse were analyzed, including the diagnosis, IPSS risk and cytogenetic risk group, treatment, disease status before transplantation, HLA disparity and the length between diagnosis and transplantation. Results of univariate analysis are shown in Table 2 . No pre-transplant factors except chemotherapy before transplantation were significantly associated with RR. The patients who received chemotherapy before transplantation were prone to relapse after transplantation (36.7 vs 0%, P ¼ 0.028). Disease duration before HSCT also seemed to have an influence on the RR as patients transplanted after the median length were prone to relapse, although the difference did not reach statistical significance (8.3 vs 30%, P ¼ 0.09).
LFS and long-term follow-up
At a median follow-up of 17 months (range 2.0-55 months), 25 patients were alive 4.2-55 months after transplantation and were all free of disease. The probability of OS and LFS were 62.98±10.18% and 64.63±9.14%, respectively, at 2 years ( Figure 1 ).
As mentioned above, three of the four relapsed patients died from recurrent disease, whereas the fourth patient died from a pulmonary fungal infection when the disease was still in CR. Overall, eight patients died from other causes rather than relapse, as shown in Table 3 . The most frequent cause of death was infection, specifically pneumonia. Five died from Aspergillus pneumonia, CMV pneumonia accounted for one patient and no pathogenic agent was identified in the remaining patients. Severe GVHD was likely the direct cause of death in one patient. The NRM rate at 2 years was 25%.
As shown in Table 2 , severity of aGVHD, HLA disparity and the disease duration before HSCT affected LFS. Three of the four patients with grade III or IV aGVHD died of GVHD directly or from complications related to it. Therefore, the aGVHD also had a significant impact on NRM. The patients who received grafts from 3-loci- mismatched donors had worse outcomes compared with recipients of 1-2-loci-mismatched donors (Figure 2 ), resulting in higher NRM in the former group. However, the severe aGVHD occurred almost equally in the two groups(2/19 vs 2/17). Patients receiving transplants after the median length experienced only a 43.1% LFS compared with the 88.9% LFS in patients who received transplant before the median measure. This might be due to the higher NRM in patients transplanted later (transplanted before the median time vs after the median time, 10.5 vs 45.6%, P ¼ 0.067). Correcting for those factors, whether patients received chemotherapy before transplantation or reached CR on transplantation had no effect on any post transplantation outcomes. We also studied the prognostic influence of age as follows: o30-years old (n ¼ 13), 30-44 years (n ¼ 14) and 445-years old (n ¼ 9). The OS at 2 years in the three groups were 61, 64.9 and 50%, respectively (P ¼ 0.79). The NRM rates were 29, 33 and 11%, respectively (P ¼ 0.63). Although the OS in the oldest group is slightly lower, this is not statistically significant and there is no difference in NRM. Our results indicate that this protocol is tolerable for patients aged 445 years.
Discussion
In this report, we described 36 patients who received mismatched HSCT and achieved sustained myeloid engraftment. The cumulative incidence rate in this cohort of grades II-IV aGVHD and severe aGVHD were 60 and 15%, respectively, which is similar to our previous reports of 55 and 23% among 171 patients with hematological malignancies treated using the same protocol. 2 The 2-year LFS was 65%. All of these findings show that our protocol is safe and effective for advanced MDS patients (RAEB, RAEBt in FAB criteria). We administer both G-PB and BM in our protocol, which can guarantee a high-dose stem cell number without causing increased aGVHD. Qualitatively, G-PB grafts have more T-polarized cells (Th2) and the MSC from G-BM may possess immunoregulatory activity. Elfenbein et al. 10 reported that the use of G-BM resulted in comparable engraftment, reduced severity of aGVHD and less subsequent cGVHD as compared with PBSC transplantation. Our own experimental data showed that the counts of T-cell subsets were different among the mixture grafts and G-PB, G-BM or the steady-state BM. 11 Further experiments confirmed that the hyporesponsiveness and polarization of T cells from Th1 to Th2 could be maintained after in vitro 
Table 3
Causes of death in the eleven patients who died during the study period
Cause
No. of patients HLA-mismatched HSCT for MDS Y Chen et al mixture of G-PB and G-BM in different proportions. 12 All of these help to reduce the incidence of GVHD and allow for the crossing of HLA barriers.
However, in patients with advanced MDS, post transplantation relapse continues to be a prevalent problem. Several studies identified relapse in 20-40% of patients with RAEB or RAEBt who received non-T-cell-depleted marrow. [13] [14] [15] [16] In a series of 452 recipients of HLA-identical sibling BM transplants for MDS, Sierra et al. 13 reported the cumulative incidence of relapse to be 17% at 1 year and 23% at 3 years (165/361 patients with blast 45% before transplantation). However, the patients with 5-20% blasts had a risk for relapse that was 2.9 times higher than patients with less than 5% blasts. As for unrelated donor marrow transplantation, the RR has been reported to be 14% at 2 years (125/510 patients belong to the refractory anemia or refractory anemia with ringed sideroblasts groups). Patients with RAEBt had 4.92 times higher rates of incidence than patients with refractory anemia. 17 In the largest cohort of mismatched HSCT, Witte et al. 18 reported that the 3-year RR was 16% for the 79 patients transplanted using non-identical donors, with the TRM being as high as 62%. The RR in our study was about 19.25±9.37%, which is comparable with the reports just discussed, especially considering that all the patients had advanced disease (blasts 45% in BM 1 ). These results indicate that HLA-mismatched transplantation has a stronger antileukemia effect, although our results may also be affected by the use of both G-BM and PBSCs as grafts. Guardiola et al. 19 reported the retrospective comparison of BM and G-PBs for allo-SCT using HLA-identical sibling donors in MDS. The overall 2-year estimated treatment failure incidence was dramatically lower in the PBSC group than in the BM group (13 vs 38%, 174/234 patients belong to the RAEB or RAEBt groups), which was seen across all MDS categories with the use of PBSC. Our previous study also showed that the cell compositions were different between G-PB and G-BM. 20, 21 Thus, it is possible that the source of stem cells affects the RR, but further study is required to validate this suggestion.
The NRM in transplantation for MDS is generally much higher than in other diseases, and the reason for this is not well understood. However, in our report, the NRM was 25.1%, which was not only much lower than the 62% reported by Witte et al. and the 54% from unrelated BMT data but also comparable with the 30% results of the European Bone Marrow Transplantation Registry, which included 543 patients who received matched related donor transplantation. 17, 18, 22 Our lower NRM shows the safety of our protocol. The superior results may reflect the specific improvements in our protocol, such as reducing the BU length of treatment from 4 days to 3 days. The Fred Hutchinson Cancer Research Center used to add BU (7 mg/ kg) given over 4 days to the CY and a fractionated TBI regimen in an attempt to reduce the high RRs. However, although there was a trend toward fewer relapses (28 vs 54%), there was an increase in NRM from 36 to 58%. 23 Therefore, the intensity of regimen had an effect on NRM. In fact, we applied the same methods to the matched HSCT for MDS and got an NRM rate of 21.43%, which was also lower than the most reports. 24 Another factor contributing to NRM may be the duration of disease before transplantation. Delayed HSCT in advanced MDS may result in disease progression or a worsening in patient conditioning, thus increasing the NRM. A study on 131 patients (who had not received intensive chemotherapy before HSCT) reported to the European Bone Marrow Transplantation Registry showed that a shorter interval from diagnosis to transplant (o1 year) was associated with better outcomes. 15 In our report, the median time to transplantation was 7 months, and most of the patients (21) had received no chemotherapy. Although the disease duration was not identified as a risk factor for NRM, patients transplanted before the median time of 7 months after diagnosis had a higher disease-free survival of 88.9%, which was statistically significant.
Owing to the lower relapse and NRM, the LFS in our cohort increased. At a median follow-up of 17 months, 25 patients were alive and free of disease. The probability of OS and LFS were 62.98 ± 10.18% and 64.63 ± 9.14% at 2 years. Witte et al. 18 had reported a 3-year OS of 35% for the 79 patients transplanted using non-identical donors and a disease-free survival rate of 31%. The estimated probability of disease-free survival at 2 years from 510 unrelated BMT was only 29%. 14 The data from the European Bone Marrow Transplantation Registry, which included 543 patients who received matched related donor transplantation, showed that the 1-year disease-free survival was 46%. 22 Our results show increased LFS was not only better than previous reports for patients who received HLAmismatched HSCT but also superior or equal to survival after HLA-identical HSCT. 17, 18, [25] [26] [27] According to the IBMTR 2008 report (CIBMTR Newsletter), 28 for patients with advanced MDS receiving HLA-identical sibling HSCT, the 3-year probabilities of survival were 59±5% vs 41±2% for those o20 years of age (n ¼ 144) and 420 years of age (n ¼ 1237), respectively. The results of this study are comparable with our earlier HLA-identical HSCT results, which showed a 3-year expected OS and LFS of 63.61 and 61.41%, respectively. 24 All of these findings suggested that the MDS could be cured by haploidentical transplantation.
This study shows that haploidentical/mismatched HSCT provided effective treatment for patients with MDS. The outcomes were similar to those of HLA-identical transplantation. Patients diagnosed with advanced MDS and given transplants early in their disease course achieve better OS. High NRM is still the main factor limiting the success of HSCT, especially because of severe GVHD and fungal infection.
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